Long term failure of endoscopic gastroplication (EndoCinch)

I Schiefke, A Zabel-Langhennig, S Neumann, J Feisthammel, J Moessner, K Caca

Gut 2005;54:752–758. doi: 10.1136/gut.2004.058354

See end of article for authors' affiliations

Correspondence to:
Professor K Caca,
Department of Medicine II,
University of Leipzig,
Philipp-Rosenthal Str 27,
04103 Leipzig, Germany;
caca@medizin.
uni-leipzig.de

Revised version received
1 December 2004
Accepted for publication
21 December 2004

Introduction: Endoluminal gastroplication (EndoCinch; Bard) has been introduced as an endoscopic treatment option in gastro-oesophageal reflux disease (GORD) patients with promising short term results. However, little is known about the long term efficacy of endoscopic suturing. The aim of this study was to evaluate prospectively the long term outcome after EndoCinch.

Patients and methods: A total of 70 patients treated with EndoCinch at a single referral centre were studied prospectively. All patients were interviewed using a standardised questionnaire regarding their symptoms and medication prior to and 18 months after EndoCinch. In addition, follow up included endoscopy, 24 hour pH monitoring, and oesophageal manometry.

Results: The procedure was well tolerated without major short or long term complications. Eighteen months after EndoCinch, 56/70 patients (80%) were considered treatment failures as their heartburn symptoms did not improve or proton pump inhibitor medication exceeded 50% of the initial dose. Endoscopy showed all sutures in situ in 12/70 (17%) patients while no remaining sutures could be detected in 18/70 (26%). In 54 and 50 patients examined, respectively, no significant changes in 24 hour pH monitoring (median pH <4/24 hours, 9.1% v 8.5%; $p=0.82$) or lower oesophageal sphincter (LOS) pressure (7.7 v 10.3 mm Hg; $p=0.051$) were observed while median LOS length slightly increased (3.0 to 3.2 cm; $p<0.05$).

Conclusion: Endoscopic gastroplication (EndoCinch) is a safe and minimally invasive endoscopic treatment for GORD with reasonable short term results. In contrast, long term outcome is disappointing, probably due to suture loss in the majority of patients. Therefore, technical improvements to ensure suture durability are mandatory before endoscopic suturing can evolve as a therapeutic option for GORD treatment.

Gastro-oesophageal reflux disease (GORD) is one of the most prevalent diseases in industrialised countries. Approximately 15–25% of adults, especially in Western countries, suffer from reflux symptoms, characterised mainly by heartburn and/or regurgitation.¹ Longstanding oesophagitis may result in Barrett's metaplasia and oesophageal adenocarcinoma.^{2–4} Currently, antireflux medication with proton pump inhibitors (PPIs) or antireflux surgery are the established options for GORD. PPIs are the therapeutic gold standard in acute, long term, or on demand therapy of GORD.^{5–8} As PPIs do not restore the antireflux barrier but merely suppress acid secretion, lifelong tablet adherence is required in most cases.

Therefore, laparoscopic antireflux surgery is often proposed as a definitive alternative, especially in young patients to correct physiological and anatomical abnormalities.^{9–10} Surgery results in a positive long term outcome in 80–90% of patients.^{11–12} However, antireflux surgery is associated with a significant morbidity and 0.3% mortality.^{9–16} Moreover, 10 years after antireflux surgery, 62% of patients have been reported to use acid suppressive therapy on a regular basis.¹⁷

In view of the limitations of PPIs and the potential risks of laparoscopic surgery, several endoscopic antireflux techniques were developed and may evolve as valuable third options. Four minimally invasive approaches have been approved recently by the FDA and introduced into clinical practice (that is, Stretta, Curon Medical Inc., Sunnyvale, California, USA; Enteryx, Boston Scientific, Natick, Massachusetts, USA; EndoCinch, Bard Endoscopic Technologies, Billerica, Massachusetts, USA; and Plicator, NDO Surgical Inc., Mansfield, Massachusetts, USA).

Among the endoluminal suturing devices, to date large scale testing has been done with the EndoCinch procedure. It was developed in the 1980s¹⁸ and received FDA approval in

2000 for clinical use as an antireflux procedure. A multicentre study in 64 patients reported striking improvement in heartburn, regurgitation, and reduction in medication use six months after EndoCinch¹⁹ while 24 hour pH monitoring and manometry showed only modest changes. In another open label prospective trial, 62% of patients were off PPI medication (defined as ≤ 4 doses/month).²⁰ Additionally, the number of episodes of oesophageal acid exposure, heartburn symptoms, and regurgitation were also reduced 12 months post EndoCinch.²⁰ However, loss of sutures or ineffective plications are a major technical problem that has not been addressed to date. As EndoCinch was shown to reduce transient lower oesophageal sphincter relaxations (tLOS) and slightly increase lower oesophageal sphincter pressure (LOSP), the pressing question is the durability of the plications.²¹

Therefore, the aim of this single centre prospective study was to evaluate the long term efficacy of EndoCinch and durability of plications, 18 months after treatment.

PATIENTS AND METHODS

Patients

Between 2000 and 2002, 70 patients (26 women (38%) and 44 men (62%)), median age 48 years (range 22–77), with symptomatic GORD underwent endoscopic gastroplication using the Bard Interventional Endoscopic Suturing System (EndoCinch) at a single centre (University of Leipzig). All

Abbreviations: GORD, gastro-oesophageal reflux disease; PPIs, proton pump inhibitors; tLOS, transient lower oesophageal sphincter relaxation; LOSP, lower oesophageal sphincter pressure; HBSS, heartburn severity scoring system; H₂RA, H₂ receptor antagonist; DMJS, DeMeester-Johnson score; IQR, interquartile range; EAT, endoscopic antireflux therapy

patients gave written informed consent and the protocol was approved by the local ethics committee.

Inclusion criteria were: symptoms of chronic heartburn and/or regurgitation (>2 years); continuous PPI medication with at least partial symptom response (decrease in frequency and severity of symptoms); age >18/<80 years; and pathological distal oesophageal acid exposure measured by 24 hour pH monitoring (pH <4 greater than 5.2%/24 hours or a DeMeester-Johnson score >14.7). Exclusion criteria were: hiatal hernia >3 cm in length; grade IV reflux oesophagitis; histological Barrett's mucosa; severe dysphagia; previous oesophageal surgery; specific motility disorders; or significant untreated medical conditions.

Patients required EndoCinch either because of incomplete response to antisecretory medication and/or refusal of lifelong medication with PPIs.

Patients meeting the inclusion and exclusion criteria were enrolled in the study and underwent the EndoCinch procedure.

Clinical assessment

Patients were evaluated by medical history, reason for EndoCinch (incomplete response to antisecretory medication or refusal of lifelong treatment with PPIs), age, sex, weight, body mass index, alcohol consumption (high alcohol consumption was defined as >70 g/week), smoking status (smoker or non-smoker within six months before study inclusion), and use of acid suppressive therapy (expressed in equivalents of standard dose—that is, omeprazole 20 mg/month) at baseline. Using a standardised GORD related questionnaire, all patients were interviewed before and at 3, 6, 12, and 18 months after EndoCinch regarding reflux symptoms (that is, frequency and severity of heartburn, regurgitation, chest or epigastric abdominal pain, dysphagia, and respiratory symptoms after a 14 day period off acid suppressive medication). The frequency of symptoms was classified according to the modified DeMeester symptom scoring system.^{22, 23}

A heartburn severity scoring system (HBSS) was calculated as previously described,^{19, 24} and a detailed history of dosage and frequency of antisecretory medication over three months before EndoCinch and 3, 6, 12, and 18 months after the procedure was taken.

Endoscopy and EndoCinch procedure

Upper gastrointestinal endoscopy was performed in all patients using a high resolution videoendoscope (Olympus, Hamburg, Germany) before, 12, and 18 months post procedure. Initially, endoscopy was carried out to assess grade of oesophagitis and size of hiatal hernia if present. Grade of oesophagitis was graded according to the Savary-Miller classification.²⁵ Follow up endoscopies assessed the integrity of plications, their position, and the grade of oesophagitis.

For EndoCinch, a metal guidewire with a spring tip was passed through the endoscope into the pylorus and the endoscope was removed. A polyvinyl dilator (54F) and overtube (60F) were passed over the guidewire. The dilator and guidewire were removed and the overtube served as a conduit for subsequent instrument passage. Another gastro-scope with the mounted sewing capsule was advanced to the level of the z line. A minimum of two plications were placed for each procedure. One or two of these plications were placed along the lesser curve, 1.5 cm and 0.5 cm below the z line. Stitches to form the plication were placed in a circumferential pattern. All patients were sedated with a combination of midazolam and propofol. The procedure was performed by two experienced endoscopists who received training in the use of the EndoCinch techniques on two

Table 1 Demographic data at baseline

Characteristic	All patients (n = 70)
Age (y)	48.4 (38.8–63.2)
Body mass index (kg/m ²)	25.4 (23.4–28.3)
Sex (male)	44 (62.9)
Smoking status (non-smoker)	59 (84.3)
High alcohol consumption	29 (41.4)

Values are median (interquartile range) or n (%).

occasions and by practising on cadaver pig models on three separate occasions.

Oesophageal 24 hour pH metry

Ambulatory pH monitoring was performed for a minimum of 20 hours after a 14 day intermission of antisecretory medication (including histamine H₂ receptor antagonists (H₂RA), PPI, and prokinetic medication; Digitrapper, Medtronic Inc., Düsseldorf, Germany) at baseline and after 12 months of follow up. A dual pH antimony catheter (sensor distance 15 cm; Medtronic Inc.) was used. The proximal sensor was passed transnasally and positioned 5 cm above the manometrically determined proximal border of the LOS.

Patients were asked to note meal times, periods of sleep, and changes in body position. The following standard parameters were analysed: DeMeester-Johnson score (DMJS), percentage of total time pH <4, and number of periods pH <4. Criteria for normalisation in patients were: cumulative percentage time with oesophageal pH <4/24 hours less than 5.2% and DeMeester and Johnson score²⁶ <14.7.

Oesophageal manometry

Oesophageal manometry, using the station pull through technique,²⁷ was performed transnasally in the supine position after a overnight fasting period of 12 hours with an eight channel low resistance constant perfusion system (Medtronic Inc.), at baseline and after 12 months of follow up.

We used a catheter consisting of polyethylene with lateral openings placed at 5 cm intervals from the distal end of the catheter. Four sensors were arranged radially around the circumference at the tip of the catheter. Static pressure (LOSP), length, and relaxation of the sphincter as well as oesophageal body peristaltic amplitude and contraction pattern were analysed. LOS was considered incompetent if the resting pressure was below 6 mm Hg and/or intra-abdominal length was <1 cm. For measurement of tubular

Figure 1 Heartburn severity score at baseline and at 3, 6, 12, and 18 months of follow up.

Table 2 Gastro-oesophageal reflux disease symptoms and proton pump inhibitor use at baseline and after 18 months of follow up

Characteristic	All patients (n = 70)			p Value
	Baseline	12 month follow up	18 month follow up	
HBSS	58.2 (41.0–76.3)	32.2 (17.9–54.4)	36.8 (14.4–46.1)	0.001
Dysphagia	8 (11.4)	4 (5.7)	5 (7.1)	
Regurgitation	21 (30.0)	15 (21.4)	23 (32.8)	
PPI use (equivalents of standard dose/months)				
None	0 (0)	7 (10.0)	4 (5.7)	
1–10	1 (1.4)	11 (15.2)	4 (5.7)	
11–20	11 (15.7)	12 (17.4)	10 (14.3)	
21–30	32 (45.7)	21 (30.4)	30 (42.9)	
>30	26 (37.1)	19 (27.1)	22 (31.4)	
H ₂ RA use	0 (0)	0 (0)	0 (0)	

Values are median (interquartile range) or n (%).

HBSS, heartburn severity scoring system; PPI, proton pump inhibitor; H₂RA, H₂ receptor antagonist.

oesophageal function, 10 wet swallows were evaluated. The definition of ineffective oesophageal motility included one or more of the following criteria: contraction amplitude in the distal oesophagus <35 mm Hg, occurrence of simultaneous contraction, or interrupted contraction waves. Impaired oesophageal motility was diagnosed if >30% of contractions were ineffective in 10 swallows of a 5 ml bolus of water.²⁷

Statistical analysis

All results were evaluated as mean (SD) or median (interquartile range (IQR)) for continuous variables, and frequency counts for categorical variables. Patients were assigned to the treatment failure group (non-responders) if HBSS at 18 months was not improved or the patient had a decrease in antisecretory medication doses to less than 50%. Data were analysed with the Mann-Whitney rank sum test. The non-parametric Wilcoxon signed rank test was used to test the significance of pH monitoring, manometry data, PPI use, and HBSS symptom score before and after the procedure. A p value <0.05 was considered significant.

RESULTS

Clinical assessment

All patients who underwent the EndoCinch procedure between September 2000 and December 2002 at the University of Leipzig were evaluated for study participation. A total of 84 patients were screened. Of these, 70 patients entered the study: 10 patients lived in another state and were unable to participate in follow up visits and four patients declined the invasive follow up studies. The EndoCinch procedure was successfully completed in all patients. Patient data regarding age, sex, body mass index, smoking status,

Figure 2 Proton pump inhibitor (PPI) use (percentage of patients with dose reduction >50%) and proportion of treatment failures (PPI reduction <50% and/or no change in heartburn severity scoring system) after 3, 6, 12, and 18 months of follow up.

Figure 3 Proton pump inhibitor (PPI) use before EndoCinch (baseline) and 18 months after EndoCinch.

and alcohol ingestion prior to EndoCinch are shown in table 1. Assessment of the questionnaire and upper gastro-intestinal endoscopy were performed as scheduled in all patients. Oesophageal manometry and 24 hour pH monitoring were available in 50 and 54 patients, respectively, included in the present trial.

HBSS score decreased after three months from 58.2 (41.0–76.3) to 15.4 (3.5–40.3). The decline was most attributable to subjective lower visual analogue scale measurements. Although median HBSS increased in the follow up period (six months, 38.6 (17.2–56.6); 12 months, 35.6 (18.4–54.5)), a significant overall improvement was still found at 18 months after the procedure (36.8 (14.4–46.1); p = 0.001) (fig 1, table 2).

On entry, all patients were dependent on daily PPIs. Figure 2 shows the percentage of patients at each visit who had at least a 50% drop in medication doses. The proportion of patients with a significant drop in medication use declined rapidly during the first six months (three months: 56/70 (80%); six months: 33/70 (47%)). During the following 12 months, the decline was more shallow (12 months: 23/70 (32%); 18 months 17/70 (24%)). After 18 months, only 4/70 (6%) patients were completely off PPIs (fig 3). Evolution of HBSS and PPI use correlated with sutures in situ after 18 months of follow up is summarised in fig 4.

According to the combined end point at 18 months (decrease in medication doses >50%, patient satisfaction

Figure 4 Post hoc analysis of heartburn severity scores (A) and proton pump inhibitor (PPI) use (B) at 3, 6, 12, and 18 months after EndoCinch, correlated with loss of sutures or sutures in situ after 18 months of follow up.

and improvement in HBSS), 14/70 (20%) were assigned to the “successfully treated group” (responders) whereas 56/70 (80%) represented the “treatment failure group” (non-responders). Thirty five of 46 (76%) patients receiving EndoCinch because of incomplete response to PPIs were non-responders while 11/46 (24%) responded to the endoscopic treatment. In contrast, 21/24 (87%) patients who refused lifelong therapy did not respond to EndoCinch

whereas 3/24 (13%) were still responders 18 months after therapy. These differences were not significant.

As judged by the endoscopist, only 4/173 (2%) sutures formed an effective plication (see fig 6A, B).

While the proportion of treatment responders declined during follow up, the proportion of patients dependent on PPIs increased continuously (fig 2).

Endoscopy

The EndoCinch procedure was finished in all patients as planned. All adverse events were mild and transient. Most frequently patients complained of retrosternal and pharyngeal pain (58/70; 83%) and nausea/vomiting (12/70; 17%) after the procedure. Symptoms resolved without treatment within one week in all patients. Eight of 70 (11%) patients had a short bleeding episode which required endoscopic treatment during EndoCinch in two cases. No blood transfusions were required.

At evaluation for EndoCinch, endoscopy revealed non-erosive oesophagitis in 26/70 (37%) patients, grade I in 26/70 (37%), grade II in 16/70 (23%), and grades in III–IV 2/70 (3%). Two patients initially showing grade III and IV oesophagitis were found to have grade II oesophagitis after four weeks of high dose PPIs prior to EndoCinch treatment (table 3). At control, 38/70 (54%) patients still showed endoscopic evidence of oesophagitis 18 months after EndoCinch. Oesophagitis status remained unchanged in 40/70 (57%) patients, was improved in 20/70 (29%), and worsened in 10/70 (14%). No significant change in oesophagitis severity was found ($p = 0.058$).

Overall, a total of 173 sutures were placed: four sutures in three patients, three sutures in 27 patients, and two sutures in 40 patients were inserted. In 18/70 (26%) patients, no suture was detected, in 30/70 (43%) two had vanished, and in 24/70 (34%) one suture was gone after 18 months of follow up (fig 5). Sutures were found in the same position as recorded at the time of implantation in 12/70 (17%) patients only. Only 1/14 (7%) of the responder subgroup had all sutures in situ while no remaining sutures were detected in 3/14 (21%) patients. In addition, in 8/14 (57%) patients only one, and in 2/14 (14%) patients, two sutures were found. In

Table 3 Baseline and follow up data for endoscopy, 24 hour pH monitoring, and manometry

Characteristic	Patients		
	Baseline	Follow up	p Value
At 12 months			
24 hour pH monitoring	n=68	n=54	
pH <4.0 (%)	9.1 (5.6–16.4)	8.5 (4.0–19.1)	0.82
DeMeester score	32.7 (20.5–59.5)	24.1 (15.2–70.4)	0.97
Oesophageal manometry	n=67	n=50	
LOS pressure (mm Hg)	7.7 (5.0–11.8)	10.3 (6.2–13.2)	0.051
LOS length (cm)	3.0 (2.0–3.5)	3.2 (2.0–4.0)	<0.05
Non-specific motility disorders (%)	29 (43.9)	22 (44.0)	
Endoscopy	n=70	n=70	
Oesophagitis (%)			
Grade 0	26 (37.1)	25 (35.7)	
Grade I	26 (37.1)	37 (52.9)	
Grade II	16 (22.9)	6 (8.6)	
Grade III/IV	2 (2.9)	2 (2.9)	
At 18 months			
Endoscopy	n=70	n=70	
Oesophagitis (%)			
Grade 0		32 (45.7)	
Grade I		27 (38.6)	
Grade II		9 (12.9)	
Grade III/IV		2 (2.9)	

Values are median (interquartile range) or n (%).
LOS, lower oesophageal sphincter.

to the judgement of the endoscopist, only 2% of the formed plications were effective after 18 months.

One possible explanation could be derived from the histopathological analysis of endoluminal gastroplications in an animal model. Feitoza and colleagues³⁶ found only shallow stitches with a flat scar, without fusion between folds, irrespective of suture penetration depth. All plications were gone after three days' survival time. As inflammation around the suture material and ischaemic areas are critical for the final outcome, further animal studies are required to assess the influence of penetration depth, knot strength, and suture length on durability of sutures.

In accordance with the observed loss of sutures only a slight, but not significant, improvement in DMJS and LOSP were observed. In addition, no changes in severity of reflux oesophagitis, a major goal in the treatment of GORD, were seen.

One putative mechanism of EndoCinch is alteration of LOS function. tLOS was significantly reduced after the procedure.²¹ The influence of endoscopic therapy on LOSP is appraised differently in different studies. We observed a modest increase in LOSP (7.7 v 10.3 mm Hg; $p = 0.051$). A similar modest increase in LOSP was reported in several other studies.^{19 21 37 38} It remains questionable at best if such a small increase in LOSP is sufficient to reduce reflux significantly.

So far the effectiveness of EATs has been mainly assessed in short term trials (six or 12 months), without an appropriate control group (medical or surgical therapy). Sham controlled trials have been completed or are underway for all endoscopic treatments of GORD.^{39 40} The first controlled trial published in 2003 included 64 patients with GORD, randomised to undergo the Stretta procedure or sham endoscopy. At six months, the Stretta procedure significantly reduced symptoms of GORD and improved quality of life compared with the sham treatment. However, the Stretta procedure did not decrease daily use of medication.³⁹ Preliminary sham controlled data also exists for the EndoCinch procedure.⁴⁰ In a single centre study, 34 patients were randomised to EndoCinch treatment or sham endoscopy. After three months of follow up, the EndoCinch procedure had reduced the frequency of GORD symptoms—61% in the EndoCinch group versus 31% in the sham group—illustrating a high placebo response rate. These data highlight the need for larger, longer, well designed trials to re-evaluate the efficacy of EATs.

Current therapy for GORD consists mainly of lifelong antisecretory medication (PPI) and laparoscopic antireflux surgery. Both strategies have disadvantages or potential hazards.^{5–12 41 42} Therefore, exploring alternative endoscopic methods is warranted. However, the solution is not simply to use the available EATs. These devices have to be shown to be effective, durable, and safe in clinical trials before they can enter the mainstream of therapeutic options for patients with GORD.

In summary, EndoCinch was shown to be safe but not as efficient as expected after 18 months of follow up. In addition, the present study demonstrated that gross loss of plications was the putative mechanism for treatment failure in the majority of patients. Additionally, a decreasing placebo effect of EndoCinch over time is possible but can only be proven in a sham controlled study. EndoCinch clearly needs refinements in the device or in the procedure before it can be considered as a treatment option for GORD patients (for example, transmural suturing,⁴³ helical transfer of sutures,⁴⁴ or additional pretreatment of suture places by supplemental cautery⁴⁵). These sobering data may help to intensify our efforts to develop improved endoluminal suturing devices with more durable and predictable results.

Authors' affiliations

I Schiefke, A Zabel-Langhennig, S Neumann, J Feisthammel, J Moessner, K Caca, Department of Medicine II, University of Leipzig, Leipzig, Germany

Conflict of interest: None declared.

REFERENCES

- Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. *Am J Dig Dis* 1976;**21**:953–6.
- Klausner AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. *Lancet* 1990;**335**:205–8.
- Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? *Scand J Gastroenterol* 1993;**28**:681–7.
- Locke GR 3rd, Talley NJ, Fett SL, et al. The prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997;**112**:1448–56.
- Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. *N Engl J Med* 1995;**333**:1106–10.
- Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. *Gastroenterology* 2000;**118**:661–9.
- Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. *Aliment Pharmacol Ther* 2000;**14**:1249–58.
- Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. *Aliment Pharmacol Ther* 2001;**15**:927–35.
- Lundell L. Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. *Gut* 2002;**51**:468–71.
- Mattoli S, Lugesani ML, Pierluigi M, et al. Indications for anti-reflux surgery in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2003;**17**(suppl 2):60–7.
- DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. *Ann Surg* 1986;**204**:9–20.
- Lundell L, Abrahamsson H, Ruth M, et al. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. *Br J Surg* 1996;**83**:830–5.
- Gotley DC, Smithers BM, Rhodes M, et al. Laparoscopic Nissen fundoplication—200 consecutive cases. *Gut* 1996;**38**:487–91.
- Bittner HB, Meyers WC, Brazer SR, et al. Laparoscopic Nissen fundoplication: operative results and short-term follow-up. *Am J Surg* 1994;**167**:193–8; discussion 199–200.
- Perdikis G, Hinder RA, Lund RJ, et al. Laparoscopic Nissen fundoplication: where do we stand? *Surg Laparosc Endosc* 1997;**7**:17–21.
- Laflorde T, Watson DI, Jamieson GG, et al. Laparoscopic Nissen fundoplication: five-year results and beyond. *Arch Surg* 2001;**136**:180–4.
- Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. *JAMA* 2001;**285**:2331–8.
- Swain CP, Mills TN. An endoscopic sewing machine. *Gastrointest Endosc* 1986;**32**:36–8.
- Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. *Gastrointest Endosc* 2001;**53**:416–22.
- Mahmood Z, McMahon BP, Arfin Q, et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. *Gut* 2003;**52**:34–9.
- Tam WC, Holloway RH, Dent J, et al. Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. *Am J Gastroenterol* 2004;**99**:195–202.
- DeMeester TR, Johnson LF, Joseph GJ, et al. Patterns of gastroesophageal reflux in health and disease. *Ann Surg* 1976;**184**:459–70.
- DeMeester TR, Johnson LF. The evaluation of objective measurements of gastroesophageal reflux and their contribution to patient management. *Surg Clin North Am* 1976;**56**:39–53.
- Reading AE. Testing pain mechanism in persons with pain. In: Melzack R, ed. *Textbook of pain*. New York, NY: Churchill Livingstone Inc, 1989:269–80.
- Savary M, Miller G. The esophagus. In: Savary M, Miller G, eds. *Handbook and atlas of endoscopy*. Solothurn, Switzerland: Verlag Gassman, 1978:119–295.
- Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. *J Clin Gastroenterol* 1986;**8**(suppl 1):52–8.
- Kahrilas PJ, Clouse RE, Hogan WJ. American Gastroenterological Association technical review on the clinical use of esophageal manometry. *Gastroenterology* 1994;**107**:1865–84.
- Chadlavadia R, Lin E, Swafford V, et al. Comparative results of endoluminal gastropasty and laparoscopic antireflux surgery for the treatment of GERD. *Surg Endosc* 2004;**18**:261–5.

- 29 **Bittinger M**, Messmann H. New endoscopic therapies for gastroesophageal reflux disease. *Z Gastroenterol* 2003;**41**:921–8.
- 30 **Caca K**. Medikamentöse versus endoskopische Therapie der Refluxkrankheit. *Z Gastroenterol* 2002;**40**:9–11.
- 31 **Galmiche JP**, Bruley des Varannes S. Endoluminal therapies for gastroesophageal reflux disease. *Lancet* 2003;**361**:1119–21.
- 32 **Abou-Rebyeh H**, Hoepffner N, Rosch T, et al. Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. *Endoscopy* 2005;**37**:213–16.
- 33 **Tuebergen D**, Rijcken E, Senninger N. Esophageal perforation as a complication of EndoCinch endoluminal gastroplication. *Endoscopy* 2004;**36**:663–5.
- 34 **Johnson DA**, Ganz R, Aisenberg J, et al. Endoscopic implantation of enterix for treatment of GERD: 12-month results of a prospective, multicenter trial. *Am J Gastroenterol* 2003;**98**:1921–30.
- 35 **Triadafilopoulos G**. Stretta: an effective, minimally invasive treatment for gastroesophageal reflux disease. *Am J Med* 2003;**115**(suppl 3A):192–2005.
- 36 **Feitoza AB**, Gostout CJ, Rajan E, et al. Understanding endoluminal gastroplications: a histopathologic analysis of intraluminal suture plications. *Gastrointest Endosc* 2003;**57**:868–76.
- 37 **Park P**, Kjellin L, Kadirkamanthan S, et al. Results of endoscopic gastroplication for gastroesophageal reflux disease. *Gastrointest Endosc* 2001;**55**:AB115.
- 38 **Schiefke I**, Soeder H, Zabel-Langhennig A, et al. Endoluminal gastroplication: what are the predictors of outcome? *Scand J Gastroenterol* 2004;**39**:1296–303.
- 39 **Corley DA**, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. *Gastroenterology* 2003;**125**:668–76.
- 40 **Rothstein RI**, Hynes ML, Grove MR, et al. Endoscopic gastric plication (EndoCinch) for GERD: a randomized, sham-controlled, blinded, single-center study. *Gastrointest Endosc* 2004;**59**:AB111.
- 41 **Chiba N**, De Gara C, Wilkinson J, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. *Gastroenterology* 1997;**112**:1798–810.
- 42 **DeVault KR**, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol* 1999;**94**:1434–42.
- 43 **Chuttani R**, Sud R, Sachdev G, et al. A novel endoscopic full-thickness plicator for the treatment of GERD: A pilot study. *Gastrointest Endosc* 2003;**58**:770–6.
- 44 **Rajiman I**, Walters R, Garza C, et al. Helical endoluminal gastroplication (ELGP) compared to standard ELGP in patients with gastroesophageal reflux disease (GERD). *Gastrointest Endosc* 2002;**55**:AB260.
- 45 **Lehman G**, Dunne D, Hieston K, et al. Suturing plication of cardia with endocinch device: Effect of supplemental cautery. A human prospective randomized trial. *Gastrointest Endosc* 2002;**55**:AB260.

EDITOR'S QUIZ: GI SNAPSHOT

Robin Spiller, Editor

Rare presentation of a common illness

Clinical presentation

A 40 year old previously healthy man presented as an emergency admission with a 10 day history of profuse watery diarrhoea up to 10 times per day but no blood in the stools. He also complained of mild headache, myalgia, and fever. He had vomiting and crampy abdominal pain two days prior to admission. He had last travelled on holiday to Sri Lanka three months prior to this admission, and at that time his daughter suffered from a self limiting diarrhoeal illness.

On examination he was pyrexial at 39°C, pulse was 120 beats/min, and he was clinically dehydrated. He had a flat soft non-distended abdomen and left iliac fossa tenderness. There were no signs of peritonism. His haemoglobin level was 112 g/l. Platelet count was 1070×10^9 , C reactive protein 289 mg/l (normal <10), and erythrocyte sedimentation rate 50 mm/h. Urea and electrolytes and liver tests were normal.

Question

An urgent unprepared colonoscopy was performed (fig 1). What is the diagnosis?

See page 763 for answer

This case is submitted by:

M M Hegde, N K Ahluwalia

Department of Gastroenterology, Stepping Hill Hospital, Stockport, UK

Correspondence to: Dr N K Ahluwalia, Department of Gastroenterology, Stepping Hill Hospital, 33 Cedar House, Stockport SK2 7JE, UK; navneet.ahluwalia@stockport-tr.nhs.uk

doi: 10.1136/gut.2004.048538

Figure 1 Caecum.